Back
 AiM  Vol.9 No.10 , October 2019
Effect of Combined Therapy on Colistin Resistant Pseudomonas aeruginosa: An in Vitro Study
Abstract: Pseudomonas aeruginosa is known for its antibiotic resistance to the clinicians. The infections caused by this pathogen are hard to treat because of its highly versatile property to mutate and acquire drug resistance. Pseudomonas aeruginosa also possesses intrinsic property of resistance to certain antibiotics like tetracyclines. However; in a practice to overcome the problem of multi drug resistance, clinicians restored the use of some antibiotics that were previously been used to treat the Pseudomonal infections; but they were discontinued because of its toxic effects. Colistin is an example of one such antibiotic. Use of Colistin was barred for its neurotoxicity. However in recent clinical trials, Colistin was reintroduced to fight with this superbug. Sadly in recent years, Pseudomonas aeruginosa developed resistance to Colistin as well. Therefore combined therapy is an alternate and suitable treatment to overcome the infections caused by multidrug-resistant Pseudomonas aeruginosa. The present study is an in vitro study; in which we tested synergy between two antibiotics namely streptomycin and Colistin on 29 clinical isolates of P. aeruginosa collected from hospitals in Jazan city KSA. The combination of two drugs showed synergistic activity on 55.1% of tested strains, while 20.6% strains had partial synergy, whereas indifferent synergy was observed in 13.8% strains and the 6.8% of strains had additive synergy. In addition to this, the drugs when combined also showed antagonism on one strain (3.44%). The present study showed synergistic action on Colistin-resistant Pseudomonas aeruginosa to greater extent (55.1%) by the two tested drugs. Hence Colistin and streptomycin can be used as a suitable combination therapy (in vivo) to treat multidrug resistant P. aeruginosa infections.
Cite this paper: Fatima, N. , Marwan, A. , Anwar, A. , Madhkhali, A. , Ali, N. , Gadi, A. , Hasnany, A. , Hamali, R. , Ayyashi, M. and Hobani, Y. (2019) Effect of Combined Therapy on Colistin Resistant Pseudomonas aeruginosa: An in Vitro Study. Advances in Microbiology, 9, 877-892. doi: 10.4236/aim.2019.910054.
References

[1]   Gellatly, S.L. and Hancock, R.E. (2013) Pseudomonas Aeruginosa: New Insights into Pathogenesis and Host Defenses. Pathogens and Disease, 67, 159-173.
https://doi.org/10.1111/2049-632X.12033

[2]   Livermore, D.M. (2002) Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas Aeruginosa: Our Worst Nightmare? Clinical Infectious Diseases, 34, 634-640.
https://doi.org/10.1086/338782

[3]   Mesaros, N., Nordmann, P., Plésiat, P., Roussel-Delvallez, M., Van Eldere, J., Glupczynski, Y., et al. (2007) Pseudomonas aeruginosa: Resistance and Therapeutic Options at the Turn of the New Millennium. Clinical Microbiology and Infection, 13, 560-578.
https://doi.org/10.1111/j.1469-0691.2007.01681.x

[4]   Aloush, V., Navon-Venezia, S., Seigman-Igra, Y., Cabili, S. and Carmeli, Y. (2006) Multidrug-Resistant Pseudomonas aeruginosa: Risk Factors and Clinical Impact. Antimicrobial Agents and Chemotherapy, 50, 43-48.
https://doi.org/10.1128/AAC.50.1.43-48.2006

[5]   Lambert, P. (2002) Mechanisms of Antibiotic Resistance in Pseudomonas aeruginosa. Journal of the Royal Society of Medicine, 95, 22.

[6]   Morita, Y., Tomida, J. and Kawamura, Y. (2014) Responses of Pseudomonas aeruginosa to Antimicrobials. Frontiers in Microbiology, 4, 422.
https://doi.org/10.3389/fmicb.2013.00422

[7]   Aly, M. and Balkhy, H.H. (2012) The Prevalence of Antimicrobial Resistance in Clinical Isolates from Gulf Corporation Council Countries. Antimicrobial Resistance and Infection Control, 1, 26.
https://doi.org/10.1186/2047-2994-1-26

[8]   Hamer, D.H. (2000) Treatment of Nosocomial Pneumonia and Tracheobronchitis Caused by Multidrug-Resistant Pseudomonas aeruginosa with Aerosolized Colistin. American Journal of Respiratory and Critical Care Medicine, 162, 328-330.
https://doi.org/10.1164/ajrccm.162.1.9910071

[9]   Hachem, R.Y., Chemaly, R.F., Ahmar, C.A., Jiang, Y., Boktour, M.R., Rjaili, G.A., et al. (2007) Colistin Is Effective in Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa in Cancer Patients. Antimicrobial Agents and Chemotherapy, 51, 1905-1911.
https://doi.org/10.1128/AAC.01015-06

[10]   Levin, A.S., Barone, A.A., Penço, J., Santos, M.V., Marinho, I.S., Arruda, E.A., et al. (1999) Intravenous Colistin as Therapy for Nosocomial Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clinical Infectious Diseases, 28, 1008-1011.
https://doi.org/10.1086/514732

[11]   Goli, H.R., Nahaei, M.R., Rezaee, M.A., Hasani, A., Kafil, H.S. and Aghazadeh, M. (2016) Emergence of Colistin Resistant Pseudomonas aeruginosa at Tabriz Hospitals, Iran. Iranian Journal of Microbiology, 8, 62.

[12]   Denton, M., Kerr, K., Mooney, L., Keer, V., Rajgopal, A., Brownlee, K., et al. (2002) Transmission of Colistin-Resistant Pseudomonas aeruginosa between Patients Attending a Pediatric Cystic Fibrosis Center. Pediatric Pulmonology, 34, 257-261.
https://doi.org/10.1002/ppul.10166

[13]   Bergen, P.J., Tsuji, B.T., Bulitta, J.B., Forrest, A., Jacob, J., Sidjabat, H.E., et al. (2011) Synergistic Killing of Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula by Colistin Combined with Doripenem in an in Vitro Pharmacokinetic/Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 55, 5685-5695.
https://doi.org/10.1128/AAC.05298-11

[14]   Cursino, L., Chartone-Souza, E. and Nascimento, A.M.A. (2005) Synergic Interaction between Ascorbic Acid and Antibiotics against Pseudomonas aeruginosa. Brazilian Archives of Biology and Technology, 48, 379-384.
https://doi.org/10.1590/S1516-89132005000300007

[15]   Gaby, W. and Hadley, C. (1957) Practical Laboratory Test for the Identification of Pseudomonas aeruginosa. Journal of Bacteriology, 74, 356.

[16]   Cavaleri, J., Rankin, D., Harbeck, J., Sautter, L., McCarter, S., Sharp, S., et al. (2005) Manual of Antimicrobial Susceptibility Testing. American Society for Microbiology, Seattle.

[17]   Andrews, J.M. (2001) Determination of Minimum Inhibitory Concentrations. Journal of Antimicrobial Chemotherapy, 48, 5-16.
https://doi.org/10.1093/jac/48.suppl_1.5

[18]   Cai, Y., Wang, R., Pei, F. and Liang, B.-B. (2007) Antibacterial Activity of Allicin Alone and in Combination with β-Lactams against Staphylococcus spp. and Pseudomonas aeruginosa. The Journal of Antibiotics, 60, 335.
https://doi.org/10.1038/ja.2007.45

[19]   Ahmed, Z., Khan, S.S. and Khan, M. (2013) In Vitro Trials of Some Antimicrobial Combinations against Staphylococcus aureus and Pseudomonas aeruginosa. Saudi Journal of Biological Sciences, 20, 79-83.
https://doi.org/10.1016/j.sjbs.2012.10.005

[20]   Memish, Z.A., Shibl, A.M., Kambal, A.M., Ohaly, Y.A., Ishaq, A. and Livermore, D.M. (2012) Antimicrobial Resistance among Non-Fermenting Gram-Negative Bacteria in Saudi Arabia. Journal of Antimicrobial Chemotherapy, 67, 1701-1705.
https://doi.org/10.1093/jac/dks091

[21]   Babay, H.A. (2007) Antimicrobial Resistance among Clinical Isolates of Pseudomonas aeruginosa from Patients in a Teaching Hospital, Riyadh, Saudi Arabia, 2001-2005. Japanese Journal of Infectious Diseases, 60, 123-125.

[22]   Somily, A.M., Absar, M.M., Arshad, M.Z., Al Aska, A.I., Shakoor, Z.A., Fatani, A.J., et al. (2012) Antimicrobial Susceptibility Patterns of Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii against Carbapenems, Colistin, and Tigecycline. Saudi Medical Journal, 33, 750-755.

[23]   Liu, Y.-Y., Wang, Y., Walsh, T.R., Yi, L.-X., Zhang, R., Spencer, J., et al. (2016) Emergence of Plasmid-Mediated Colistin Resistance Mechanism MCR-1 in Animals and Human Beings in China: A Microbiological and Molecular Biological Study. The Lancet Infectious Diseases, 16, 161-168.
https://doi.org/10.1016/S1473-3099(15)00424-7

[24]   Sonnevend, Á., Ghazawi, A., Alqahtani, M., Shibl, A., Jamal, W., Hashmey, R., et al. (2016) Plasmid-Mediated Colistin Resistance in Escherichia coli from the Arabian Peninsula. International Journal of Infectious Diseases, 50, 85-90.
https://doi.org/10.1016/j.ijid.2016.07.007

[25]   Leangapichart, T., Gautret, P., Brouqui, P., Mimish, Z., Raoult, D. and Rolain, J.-M. (2016) Acquisition of mcr-1 Plasmid-Mediated Colistin Resistance in Escherichia coli and Klebsiella pneumoniae during Hajj 2013 and 2014. Antimicrobial Agents and Chemotherapy, 60, 6998-6999.
https://doi.org/10.1128/AAC.01486-16

[26]   Zowawi, H.M. (2016) Antimicrobial Resistance in Saudi Arabia: An Urgent Call for an Immediate Action. Saudi Medical Journal, 37, 935.
https://doi.org/10.15537/smj.2016.9.16139

[27]   Vidaillac, C., Benichou, L. and Duval, R.E. (2012) In Vitro Synergy of Colistin Combinations against Colistin-Resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae Isolates. Antimicrobial Agents and Chemotherapy, 56, 4856-4861.
https://doi.org/10.1128/AAC.05996-11

[28]   Hancock, R., Raffle, V.J. and Nicas, T.I. (1981) Involvement of the Outer Membrane in Gentamicin and Streptomycin Uptake and Killing in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 19, 777-785.
https://doi.org/10.1128/AAC.19.5.777

[29]   Poole, K. (2005) Aminoglycoside Resistance in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 49, 479-487.
https://doi.org/10.1128/AAC.49.2.479-487.2005

[30]   Cervantes-Vega, C., ChÁvez, J. and Rodríguez, M. (1986) Antibiotic Susceptibility of Clinical Isolates of Pseudomonas aeruginosa. Antonie Van Leeuwenhoek, 52, 319-324.
https://doi.org/10.1007/BF00428643

 
 
Top